Cyclacel raises up to $33M via Lazar & Helena equity lines; stockholders approve reverse split and share increases

Bio Green Med Solution, Inc.

Lazar purchase agreement: up to $8M in Common Stock, exercisable by company until Sept 30, 2026, in $1M/$2M increments.
Helena equity line: up to $25M over 36 months; initial commitment shares $125K; purchases at 95% of VWAP, min stock price $0.20.
Amended Armistice exchange: $1.1M cash deferred to Q1 2025 filing; additional 100,000 shares issued subject to stockholder approval (received).
Stockholders approved reverse stock split (1:4 to 1:16), authorized shares increase to 250M, and issuances to Lazar and Armistice.
Company believes it has regained Nasdaq minimum stockholders' equity of $2.5M after these transactions and Cyclacel Ltd. deconsolidation.

item 1.01 item 5.07 item 3.02 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.